Fostamatinib (Tavalisse)
General information
Class/mechanism: Spleen tyrosine kinase (SYK) inhibitor. The main metabolite of fostamatinib is R406, which reduces antibody-mediated destruction of platelets. R406 also inhibits signal transduction of Fc-activating receptors and B-cell receptor.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Preliminary data
Diffuse large B-cell lymphoma; Follicular lymphoma
- Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, Schaefer-Cutillo J, De Vos S, Sinha R, Leonard JP, Cripe LD, Gregory SA, Sterba MP, Lowe AM, Levy R, Shipp MA. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010 Apr 1;115(13):2578-85. Epub 2009 Nov 17. link to original article PubMed
Patient drug information
History of changes in FDA indication
- 4/17/2018: Granted FDA regular approval "for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment."
Also known as
- Code names: R788, R935788